Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Caporali R, Allanore Y, Alten R, Combe B, Durez P, Iannone F, Nurmohamed MT, Lee SJ, Kwon TS, Choi JS, Park G, Yoo DH. Caporali R, et al. Among authors: alten r. Expert Rev Clin Immunol. 2021 Jan;17(1):85-99. doi: 10.1080/1744666X.2020.1858803. Epub 2020 Dec 28. Expert Rev Clin Immunol. 2021. PMID: 33305638 Free article.
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C. Conaghan PG, et al. Ann Rheum Dis. 2013 Aug;72(8):1287-94. doi: 10.1136/annrheumdis-2012-201611. Epub 2012 Aug 21. Ann Rheum Dis. 2013. PMID: 22915624 Free PMC article. Clinical Trial.
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.
van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, Curiale C, Gómez-Centeno A, Haugeberg G, Leeb B, Puolakka K, Ravelli A, Rintelen B, Sarzi-Puttini P. van Riel P, et al. Among authors: alten r. RMD Open. 2016 Nov 24;2(2):e000302. doi: 10.1136/rmdopen-2016-000302. eCollection 2016. RMD Open. 2016. PMID: 27933206 Free PMC article. Review.
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
Alten R, Batko B, Hala T, Kameda H, Radominski SC, Tseluyko V, Babic G, Cronenberger C, Hackley S, Rehman M, von Richter O, Zhang M, Cohen S. Alten R, et al. RMD Open. 2019 Mar 28;5(1):e000876. doi: 10.1136/rmdopen-2018-000876. eCollection 2019. RMD Open. 2019. PMID: 30997153 Free PMC article. Clinical Trial.
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
Kim H, Alten R, Cummings F, Danese S, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L. Kim H, et al. Among authors: alten r. MAbs. 2021 Jan-Dec;13(1):1868078. doi: 10.1080/19420862.2020.1868078. MAbs. 2021. PMID: 33557682 Free PMC article. Review.
233 results